April 3, 2017 07:10 PM EDT

Paratek shares shoot up on a positive PhIII and a slow-mo shot at FDA/EMA OK for its antibiotic

John Carroll

Editor & Founder

Shares of Paratek shot up 30% $PRTK in after-market trading on Monday as investors reacted to the Boston biotech’s proclamation of a clean sweep for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Paratek shares shoot up on a positive PhIII and a slow-mo shot at FDA/EMA OK for its antibiotic

John Carroll

Editor & Founder

Sign up to read this article for free.

Regeneron buys London-based ocular biotech

A look at biotech's year of the megaround

Biopharma to raise more than 1,000 drug prices in 2025, advisory firm predicts

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

Roche circles back to China biotech with $80M deal for lung cancer ADC

Neumora's major depression drug flunks first of three Phase 3 trials

Paratek shares shoot up on a pos­i­tive PhI­II and a slow-mo shot at FDA/EMA OK for its an­tibi­ot­ic

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Re­gen­eron buys Lon­don-based oc­u­lar biotech

A look at biotech's year of the megaround

Bio­phar­ma to raise more than 1,000 drug prices in 2025, ad­vi­so­ry firm pre­dicts

Penn­syl­va­nia Blue Cross in­sur­er re­stricts cov­er­age of med­i­cines grant­ed FDA ac­cel­er­at­ed ap­proval

Roche cir­cles back to Chi­na biotech with $80M deal for lung can­cer ADC

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

Paratek shares shoot up on a positive PhIII and a slow-mo shot at FDA/EMA OK for its antibiotic

Regeneron buys London-based ocular biotech

Biopharma to raise more than 1,000 drug prices in 2025, advisory firm predicts

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

Roche circles back to China biotech with $80M deal for lung cancer ADC

Neumora's major depression drug flunks first of three Phase 3 trials